GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Metabolic Influences on Complex Tumor Neighborhoods

$925,000
M. Celeste Simon · University Of Pennsylvania · R35 · FY2023 · CA

INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

$924,838
Rosa Maria Diaz · Vyriad, Inc. · R44 · FY2018 · CA

Mesothelin-targeted immunotoxins in Pancreatic Cancer

$924,682
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host

$924,071
Ronald Levy · Stanford University · R35 · FY2016 · CA

Signal Transduction Events and the Regulation of Cell Growth

$923,994
Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2019 · CA

Exploring DNA damage response pathways as targets for cancer therapy

$923,400
Junjie Chen · University Of Tx Md Anderson Can Ctr · R35 · FY2024 · CA

Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer

$923,254
Emek Demir · Oregon Health & Science University · U2C · FY2023 · CA

Data Processing, Analysis and Modeling Unit

$923,254
Jeremy Goecks · Oregon Health & Science University · U2C · FY2023 · CA

Systems genetics analysis of tumor evolution in the mouse

$922,470
Allan Balmain · University Of California, San Francisco · R35 · FY2019 · CA

Metabolic Influences on Complex Tumor Neighborhoods

$921,582
M. Celeste Simon · University Of Pennsylvania · R35 · FY2024 · CA

A single-cell device to capture and analyze rare T-cells from solid tumors.

$920,072
Timothy S McConnell · Isoplexis, Inc. · R44 · FY2018 · CA

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas

$919,541
Darell D Bigner · Duke University · R35 · FY2021 · CA

Specialized Program Of Research Excellence (SPORE) in Leukemia.

$918,606
Daniel C Link · Washington University · P50 · FY2023 · CA

Next Generation Cancer Immunotherapies to Defeat Melanoma

$917,279
Antoni Ribas · University Of California Los Angeles · R35 · FY2023 · CA

Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences

$916,550
Dennis E. Discher · University Of Pennsylvania · U01 · FY2021 · CA

Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation

$915,790
Robert J Coffey · Vanderbilt University Medical Center · R35 · FY2025 · CA

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas

$912,796
Darell D Bigner · Duke University · R35 · FY2018 · CA

Regulation of stem cell development during tissue remodeling

$911,209
Yun-Bo Shi · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2015 · HD

Optimizing AAV delivery of bNAbs for HIV prevention

$909,998
Matthew Ryan Gardner · Emory University · R01 · FY2023 · AI

Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host

$909,837
Ronald Levy · Stanford University · R35 · FY2017 · CA

Human Monoclonal Antibodies Against Cancer

$909,717
Dimiter S Dimitrov · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

$909,357
Luke O. Russell · Vyriad, Inc. · R44 · FY2019 · CA

Optimizing AAV delivery of bNAbs for HIV prevention

$908,948
Matthew Ryan Gardner · Emory University · R01 · FY2024 · AI

Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy

$908,910
Michael Demetriou · Glytr Therapeutics, Inc. · R42 · FY2024 · CA

Targeting Gq pathway in uveal melanoma

$908,647
Xu Chen · University Of California, San Francisco · R01 · FY2025 · CA